Overview

(Common)
Exchange	(US Dollar)
Price
Change (%)

Data as of January 24, 2021 10:33 am EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Summary Toggle Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-W

November 13, 2020

Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH : Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™ , AASLD Product Theater on Friday , November 13 , 2020 , at 4:30 PM ET . In the 100 mg open label arm of MAESTRO-NAFLD : At week
Summary Toggle Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

November 05, 2020

CONSHOHOCKEN, Pa. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments.
Summary Toggle Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 W

October 01, 2020

High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO- NASH study using clinical characteristics and simple, readily available non-invasive imaging and biomarkers Data from ongoing MAESTRO-NAFLD-1 open label arm confirm robust liver fat reduction on MRI- PDFF and reduction

SEC Filings

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf